Gilead Sciences, Inc. (GILD)

NASDAQ: GILD · Real-Time Price · USD
114.54
+1.30 (1.15%)
Jul 10, 2025, 4:00 PM - Market closed
1.15%
Market Cap 142.48B
Revenue (ttm) 28.74B
Net Income (ttm) 5.97B
Shares Out 1.24B
EPS (ttm) 4.73
PE Ratio 24.21
Forward PE 14.08
Dividend $3.16 (2.76%)
Ex-Dividend Date Jun 13, 2025
Volume 6,097,178
Open 113.07
Previous Close 113.24
Day's Range 112.83 - 114.87
52-Week Range 67.65 - 119.96
Beta 0.31
Analysts Buy
Price Target 110.17 (-3.82%)
Earnings Date Aug 7, 2025

About GILD

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]

Sector Healthcare
IPO Date Jan 22, 1992
Employees 17,600
Stock Exchange NASDAQ
Ticker Symbol GILD
Full Company Profile

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial Statements

Analyst Summary

According to 25 analysts, the average rating for GILD stock is "Buy." The 12-month stock price target is $110.17, which is a decrease of -3.82% from the latest price.

Price Target
$110.17
(-3.82% downside)
Analyst Consensus: Buy
Stock Forecasts

News

AHF: Gilead's Greed Costs Latin America HIV Protection

MEXICO CITY--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundbreaking HIV p...

1 day ago - Business Wire

Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million

Gilead Sciences, Inc. GILD on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead's twice-yearly injectabl...

1 day ago - Benzinga

Gilead, Global Fund finalize plan to supply HIV prevention drug to poor countries

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite the ...

1 day ago - Reuters

Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) ...

1 day ago - Business Wire

Final Trades: Synovus, Nextera Energy, Gilead and the IYF

The Investment Committee give you their top stocks to watch for the second half.

Other symbols: IYFNEESNV
2 days ago - CNBC Television

Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others

Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.

Other symbols: BMYJNJNVOPFEVRTX
2 days ago - CNBC

It is time for a move higher in biotech, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.

Other symbols: BBIOBMRNINSMXBI
3 days ago - CNBC Television

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

nvestors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance o...

Other symbols: FNVJCINOCUSFD
5 days ago - Benzinga

Gilead shares rise after US top court ruling on preventative coverage

Shares of Gilead rose nearly 3% after the U.S. Supreme Court on Friday preserved a key element of the Obamacare law that helps guarantee that health insurers cover preventive care at no cost to patien...

13 days ago - Reuters

Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday.

Other symbols: KYMR
15 days ago - Reuters

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

FOSTER CITY, Calif. & WATERTOWN, Mass.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive opt...

Other symbols: KYMR
15 days ago - Business Wire

Gilead Sciences CEO Daniel O'Day on HIV prevention injection approval

Gilead Sciences CEO Daniel O'Day explains why he believes the biopharma's HIV prevention injection Yeztugo, which received approval from the Food and Drug Administration last week, is a "milestone mom...

17 days ago - CNBC Television

Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV

Gilead Sciences chairman and CEO Daniel O'Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention medication, how the twice-yearly antiviral drug Yeztugo works, the importan...

17 days ago - CNBC Television

AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention

LOS ANGELES--(BUSINESS WIRE)--AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention.

22 days ago - Business Wire

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company's injectable...

22 days ago - Business Wire

FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option

The Food and Drug Administration approved Gilead's twice-yearly antiviral drug for preventing HIV. The company and some experts say it is a milestone that could help bring the world closer to ending t...

22 days ago - CNBC

US FDA approves Gilead's twice-yearly injection for HIV prevention

The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.

22 days ago - Reuters

Should You Buy Gilead Stock At $110?

Despite a recent setback with an FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performa...

22 days ago - Forbes

Gilead Sciences, Inc. (GILD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") ...

23 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gilead Sciences, Inc. (GILD) and Encourages Stockholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") ...

24 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Gilead Sciences, Inc. (GILD) Investors to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") ...

25 days ago - Accesswire

Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline

Initiate Gilead Sciences with Strong Buy/$181 PT, citing disciplined cost base, accelerating pipeline, and robust Q1-25 execution driving margin and EPS outperformance. HIV franchise resilience and up...

25 days ago - Seeking Alpha

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gilead Sciences, Inc. (GILD) And Encourages Investors to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") ...

27 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gilead Sciences, Inc. (GILD) And Encourages Stockholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") ...

4 weeks ago - Accesswire

Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Gilead Sciences, Inc. (NASDAQ:GILD) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET Company Participants Daniel P. O'Day - Chairman & CEO Conference Call Participants...

4 weeks ago - Seeking Alpha